Gradalis KOL Discussion: Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer
About The Event
Join us for a virtual KOL event with Gradalis, featuring Rodney P. Rocconi, MD (Director, Cancer Center & Research Institute and Professor, Gynecologic Oncology at the University of Mississippi Medical Center) who will discuss the unmet medical need and current treatment landscape for patients suffering from ovarian cancer, along with the potential for Vigil®, a fully personalized, patient-specific cancer immunotherapy, to have applications across multiple solid tumor types including ovarian cancer.
John Nemunaitis, MD (Chief Scientific Officer, Gradalis) will present on the Vigil mechanism, highlighting how it uses the patient’s own tumor as the antigen source. Vigil is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient’s unique “clonal” tumor neoantigens.
A live question and answer session will follow the formal presentations.